Bayer: New data shows positive effect of kidney disease treatment drug

By Thomson Reuters Aug 29, 2022 | 2:25 AM

BERLIN (Reuters) – Bayer said that new data presented on Monday highlighted the potential of finerenone, compared with a placebo, to reduce the incidence of sudden cardiac death in a broad range of patients, including early and late stages of chronic kidney disease associated with type 2 diabetes.

(Writing by Miranda Murray; Editing by Paul Carrel)